abrdn plc Has $9.53 Million Stock Holdings in Structure Therapeutics Inc. (NASDAQ:GPCR)

abrdn plc grew its stake in Structure Therapeutics Inc. (NASDAQ:GPCR) by 132.7% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 217,083 shares of the company’s stock after buying an additional 123,789 shares during the period. abrdn plc owned 0.47% of Structure Therapeutics worth $9,528,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Sandia Investment Management LP acquired a new stake in shares of Structure Therapeutics in the second quarter valued at about $39,000. Quarry LP acquired a new stake in Structure Therapeutics during the second quarter worth approximately $79,000. Mirae Asset Global Investments Co. Ltd. grew its stake in Structure Therapeutics by 60.1% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,784 shares of the company’s stock worth $158,000 after purchasing an additional 1,420 shares during the period. Bank Pictet & Cie Europe AG acquired a new stake in Structure Therapeutics during the third quarter worth approximately $206,000. Finally, Mather Group LLC. acquired a new stake in Structure Therapeutics during the second quarter worth approximately $214,000. Institutional investors and hedge funds own 91.78% of the company’s stock.

Structure Therapeutics Stock Performance

GPCR stock opened at $41.14 on Friday. Structure Therapeutics Inc. has a twelve month low of $26.61 and a twelve month high of $74.21. The stock’s 50 day moving average is $39.57 and its 200-day moving average is $39.77.

Structure Therapeutics (NASDAQ:GPCR) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.18) EPS for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.05. As a group, equities analysts predict that Structure Therapeutics Inc. will post -0.79 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts recently commented on GPCR shares. JMP Securities decreased their target price on Structure Therapeutics from $91.00 to $86.00 and set a “market outperform” rating for the company in a research note on Friday, August 9th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $65.00 target price on shares of Structure Therapeutics in a research note on Monday, September 23rd. Finally, Morgan Stanley started coverage on Structure Therapeutics in a research note on Monday, September 23rd. They set an “overweight” rating and a $118.00 target price for the company. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $86.80.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.